Clinical data | |
---|---|
Other names | Endiemal, metharbitone, methobarbitone[1] |
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.011 ![]() |
Chemical and physical data | |
Formula | C9H14N2O3 |
Molar mass | 198.222 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Metharbital was patented in 1905 by Emil Fischer working for Merck.[2] It was marketed as Gemonil by Abbott Laboratories. It is a barbiturate anticonvulsant, used in the treatment of epilepsy.[3][4] It has similar properties to phenobarbital.
Metharbital can be synthesized from 2,2-diethylmalonic acid and O-methylisourea.[5][6][2]
Alcohols | |
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids | |
Imidazoles | |
Kava constituents |
|
Monoureides |
|
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|